ClinicalTrials.gg
CompletedNCT02300025Updated Feb 19, 2016Results posted

A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage

A Phase 1 interventional study of cobimetinib in Healthy Volunteer, sponsored by Genentech, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-02-19.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 74 Years
Sex
All
01

Study summary

This study is an open-label, multi-center, single-dose, parallel group study to determine the pharmacokinetics, safety, and tolerability of cobimetinib administered at 10 mg to fasted male and female adult subjects with varying degrees of hepatic function. The study will be conducted based on the Child-Pugh classification of hepatic impairment. The anticipated duration of the study is 7.5 weeks. The target sample sizes are: 18 volunteers with varying degrees of hepatic function and up to 12 healthy control volunteers.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects between 18 and 74 years of age, inclusive
  • Body weight >/=45 kg and between 17 and 41 kg/m2, inclusive
  • Subjects with hepatic impairment must have a score of 5 to 6 (mild), 7 to 9 (moderate), or 10 to 15 (severe) and have stable hepatic insufficiency within 1 month prior to Screening and a stable medication regimen for at least 1 month prior to Check-in
  • Agreement to use highly effective methods as defined in the protocol

Exclusion criteria

Exclusion Criteria:

  • Significant illness, including infections, or hospitalization within the 2 weeks prior to dosing, except for subjects with hepatic impairment who due to their liver disease may be affected by significant medical problems which require frequent hospitalizations. Invasive systemic fungal infections need to be fully treated prior to study entry
  • Significant history or clinical manifestations of any cardiac event that would put the subject at risk in the opinion of the Investigator
  • Use of drugs of abuse within 1 month of Screening or during the entire study
  • Any acute or chronic condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Cohort 1: Normal function

    Drug: cobimetinib

  • Experimental
    Cohort 2: Mild Hepatic Impairment

    Drug: cobimetinib

  • Experimental
    Cohort 3: Moderate Hepatic Impairment

    Drug: cobimetinib

  • Experimental
    Cohort 4: Severe Hepatic Impairment

    Drug: cobimetinib

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Pre-dose (0 hours [hrs]), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose

  3. Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]

    AUC (0-t) was defined as area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t).

    Time frame: Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose

  4. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

    AUC (0 - ∞) was defined as AUC from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t- ∞).

    Time frame: Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose

  5. Extrapolated Area Under the Curve (AUC Percent [%] Extrapolated)

    AUC% extrapolated was defined as the percentage of AUC \[0-∞\] obtained by forward extrapolation. It is calculated as \[AUC (0-∞) minus AUC(0-t\]\*100/ AUC (0-∞), where AUC \[0-∞\] = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-∞) and AUC(0-t) is area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration.

    Time frame: Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose

  6. Apparent Terminal Elimination Rate Constant (λZ)

    λZ was defined as the magnitude of the slope of the linear regression of the log concentration versus time profile during the terminal phase.

    Time frame: Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose

  7. Plasma Decay Half-Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration of cobimetinib to decrease by one half.

    Time frame: Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose

  8. Apparent Oral Clearance (CL/F)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose

  9. Apparent Volume of Distribution (Vz/F)

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F after the oral dose is influenced by the fraction absorbed.

    Time frame: Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose

07

Results

Posted Feb 19, 2016

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: Normal Hepatic FunctionCohort 2: Mild Hepatic ImpairmentCohort 3: Moderate Hepatic ImpairmentCohort 4: Severe Hepatic Impairment
Started10666
Completed10666
Not completed0000

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
Pre-dose (0 hours [hrs]), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose
Reported as:
Mean · nanograms per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax)
nanograms per milliliter (ng/mL)Cohort 1: Normal Hepatic FunctionCohort 2: Mild Hepatic ImpairmentCohort 3: Moderate Hepatic ImpairmentCohort 4: Severe Hepatic Impairment
Maximum Observed Plasma Concentration (Cmax)10.7 ± 7.419.00 ± 4.098.03 ± 2.493.97 ± 1.77
Statistical analysis
  • Cohort 1: Normal Hepatic Function vs Cohort 2: Mild Hepatic Impairment · Ls means ratio: 92.2 · 90% CI 59.2 to 143.4The 90% CI for differences in LS means between test and reference treatments obtained from mixed model were also back-transformed to give 90% CIs for the ratio of the test treatment relative to the reference treatment.
  • Cohort 1: Normal Hepatic Function vs Cohort 3: Moderate Hepatic Impairment · Ls means ratio: 84.9 · 90% CI 54.6 to 132.1The 90% CI for differences in LS means between the test and reference treatments obtained from the mixed model were also back-transformed to give 90% CIs for the ratio of the test treatment relative to the reference treatment.
  • Cohort 1: Normal Hepatic Function vs Cohort 4: Severe Hepatic Impairment · Ls means ratio: 39.0 · 90% CI 25.1 to 60.7The 90% CI for differences in LS means between the test and reference treatments obtained from the mixed model were also back-transformed to give 90% CIs for the ratio of the test treatment relative to the reference treatment.
PrimaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose
Reported as:
Median · hrs
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hrsCohort 1: Normal Hepatic FunctionCohort 2: Mild Hepatic ImpairmentCohort 3: Moderate Hepatic ImpairmentCohort 4: Severe Hepatic Impairment
Time to Reach Maximum Observed Plasma Concentration (Tmax)2 (1 to 6)6 (2 to 6)4 (2 to 6)2 (1 to 4)
PrimaryArea Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]

AUC (0-t) was defined as area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t).

Time frame:
Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]
ng*hr/mLCohort 1: Normal Hepatic FunctionCohort 2: Mild Hepatic ImpairmentCohort 3: Moderate Hepatic ImpairmentCohort 4: Severe Hepatic Impairment
Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]604 ± 606498 ± 200539 ± 296268 ± 181
Statistical analysis
  • Cohort 1: Normal Hepatic Function vs Cohort 2: Mild Hepatic Impairment · Ls means ratio: 98.4 · 90% CI 52.0 to 186.0The 90% CI for differences in LS means between the test and reference treatments obtained from the mixed model were also back-transformed to give 90% CIs for the ratio of the test treatment relative to the reference treatment.
  • Cohort 1: Normal Hepatic Function vs Cohort 3: Moderate Hepatic Impairment · Ls means ratio: 102.2 · 90% CI 54.0 to 193.2The 90% CI for differences in LS means between the test and reference treatments obtained from the mixed model were also back-transformed to give 90% CIs for the ratio of the test treatment relative to the reference treatment.
  • Cohort 1: Normal Hepatic Function vs Cohort 4: Severe Hepatic Impairment · Ls means ratio: 42.5 · 90% CI 22.5 to 80.5The 90% CI for differences in LS means between the test and reference treatments obtained from the mixed model were also back-transformed to give 90% CIs for the ratio of the test treatment relative to the reference treatment.
PrimaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

AUC (0 - ∞) was defined as AUC from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t- ∞).

Time frame:
Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
ng*hr/mLCohort 1: Normal Hepatic FunctionCohort 2: Mild Hepatic ImpairmentCohort 3: Moderate Hepatic ImpairmentCohort 4: Severe Hepatic Impairment
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]637 ± 606530 ± 206579 ± 301370 ± 163
Statistical analysis
  • Cohort 1: Normal Hepatic Function vs Cohort 2: Mild Hepatic Impairment · Ls means ratio: 97.6 · 90% CI 59.3 to 160.6The 90% CI for differences in LS means between the test and reference treatments obtained from the mixed model were also back-transformed to give 90% CIs for the ratio of the test treatment relative to the reference treatment.
  • Cohort 1: Normal Hepatic Function vs Cohort 3: Moderate Hepatic Impairment · Ls means ratio: 103.0 · 90% CI 62.6 to 169.6The 90% CI for differences in LS means between the test and reference treatments obtained from the mixed model were also back-transformed to give 90% CIs for the ratio of the test treatment relative to the reference treatment.
  • Cohort 1: Normal Hepatic Function vs Cohort 4: Severe Hepatic Impairment · Ls means ratio: 68.5 · 90% CI 40.4 to 116.2The 90% CI for differences in LS means between the test and reference treatments obtained from the mixed model were also back-transformed to give 90% CIs for the ratio of the test treatment relative to the reference treatment.
PrimaryExtrapolated Area Under the Curve (AUC Percent [%] Extrapolated)

AUC% extrapolated was defined as the percentage of AUC \[0-∞\] obtained by forward extrapolation. It is calculated as \[AUC (0-∞) minus AUC(0-t\]\*100/ AUC (0-∞), where AUC \[0-∞\] = Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-∞) and AUC(0-t) is area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration.

Time frame:
Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose
Reported as:
Mean · % extrapolated
Extrapolated Area Under the Curve (AUC Percent [%] Extrapolated)
% extrapolatedCohort 1: Normal Hepatic FunctionCohort 2: Mild Hepatic ImpairmentCohort 3: Moderate Hepatic ImpairmentCohort 4: Severe Hepatic Impairment
Extrapolated Area Under the Curve (AUC Percent [%] Extrapolated)7.37 ± 4.376.69 ± 2.638.17 ± 4.3615.90 ± 4.79
PrimaryApparent Terminal Elimination Rate Constant (λZ)

λZ was defined as the magnitude of the slope of the linear regression of the log concentration versus time profile during the terminal phase.

Time frame:
Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose
Reported as:
Mean · 1 per hr (1/hr)
Apparent Terminal Elimination Rate Constant (λZ)
1 per hr (1/hr)Cohort 1: Normal Hepatic FunctionCohort 2: Mild Hepatic ImpairmentCohort 3: Moderate Hepatic ImpairmentCohort 4: Severe Hepatic Impairment
Apparent Terminal Elimination Rate Constant (λZ)0.00942 ± 0.002590.00852 ± 0.003150.00702 ± 0.001810.00509 ± 0.00114
PrimaryPlasma Decay Half-Life (t1/2)

Plasma decay half-life is the time measured for the plasma concentration of cobimetinib to decrease by one half.

Time frame:
Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose
Reported as:
Mean · hr
Plasma Decay Half-Life (t1/2)
hrCohort 1: Normal Hepatic FunctionCohort 2: Mild Hepatic ImpairmentCohort 3: Moderate Hepatic ImpairmentCohort 4: Severe Hepatic Impairment
Plasma Decay Half-Life (t1/2)79.1 ± 22.795.2 ± 48.2104.0 ± 24.4143.0 ± 40.4
PrimaryApparent Oral Clearance (CL/F)

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose
Reported as:
Mean · Liter per hr (L/hr)
Apparent Oral Clearance (CL/F)
Liter per hr (L/hr)Cohort 1: Normal Hepatic FunctionCohort 2: Mild Hepatic ImpairmentCohort 3: Moderate Hepatic ImpairmentCohort 4: Severe Hepatic Impairment
Apparent Oral Clearance (CL/F)23.4 ± 11.622.9 ± 13.221.9 ± 11.731.7 ± 14.5
PrimaryApparent Volume of Distribution (Vz/F)

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F after the oral dose is influenced by the fraction absorbed.

Time frame:
Pre-dose (0 hrs), 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, 216, 264, 336, 456, and 576 hrs post-dose
Reported as:
Mean · Liter
Apparent Volume of Distribution (Vz/F)
LiterCohort 1: Normal Hepatic FunctionCohort 2: Mild Hepatic ImpairmentCohort 3: Moderate Hepatic ImpairmentCohort 4: Severe Hepatic Impairment
Apparent Volume of Distribution (Vz/F)2580 ± 13002880 ± 13703230 ± 16506280 ± 2480

Adverse events

Collected over Up to 30 days after the last dose of study drug (up to approximately 2 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Normal Hepatic Function—0/10 (0%)3/10 (30%)
Cohort 2: Mild Hepatic Impairment—0/6 (0%)3/6 (50%)
Cohort 3: Moderate Hepatic Impairment—0/6 (0%)2/6 (33.3%)
Cohort 4: Severe Hepatic Impairment—0/6 (0%)1/6 (16.7%)
Most frequent other events
Most frequent other events
EventCohort 1: Normal Hepatic FunctionCohort 2: Mild Hepatic ImpairmentCohort 3: Moderate Hepatic ImpairmentCohort 4: Severe Hepatic Impairment
DyspepsiaGastrointestinal disorders0/101/60/60/6
Abdominal painGastrointestinal disorders0/100/61/60/6
Gastrooesophageal reflux diseaseGastrointestinal disorders0/100/61/60/6
Vessel puncture site haematomaGeneral disorders0/101/60/60/6
Muscle strainInjury, poisoning and procedural complications0/100/61/60/6
DizzinessNervous system disorders0/101/60/60/6
HeadacheNervous system disorders1/100/60/61/6
HaematocheziaGastrointestinal disorders1/100/60/60/6
GoutMetabolism and nutrition disorders1/100/60/60/6
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/100/60/60/6

Baseline characteristics

Safety population included all participants who received at least one dose of cobimetinib and had at least one post-dose safety assessment.

Age, Continuous
Age, Continuous(Years)Cohort 1: Normal Hepatic FunctionCohort 2: Mild Hepatic ImpairmentCohort 3: Moderate Hepatic ImpairmentCohort 4: Severe Hepatic ImpairmentTotal
Mean56 ± 6.859 ± 2.861 ± 2.953 ± 5.357 ± 5.6
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Normal Hepatic FunctionCohort 2: Mild Hepatic ImpairmentCohort 3: Moderate Hepatic ImpairmentCohort 4: Severe Hepatic ImpairmentTotal
Female33129
Male735419
08

Study locations

3 sites
  • Anaheim, California 92801, United States
  • Miami, Florida 330014, United States
  • Orlando, Florida 32809, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2014
First posted
Nov 24, 2014
Start
Aug 2014
Primary completionActual
Jan 2015
CompletionActual
Jan 2015
Results first posted
Feb 19, 2016
Last update
Feb 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02300025
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Nov 24, 2014
Start date
Aug 2014
Primary completion
Jan 2015
Completion
Jan 2015
Results posted
Feb 19, 2016
Last update
Feb 19, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cobimetinib

Start the discussion